Cancer treatment denied

London

A breast cancer patient this week sued Britain’s National Health Service for refusing to give her a drug that could save her life. Elaine Barber, a 41-year-old mother of four, was told that prescribing Herceptin, a new drug that costs up to $50,000 a year per patient, was not “a cost-effective use of finite health resources.” Last month, though, a different patient was given the drug on the grounds that her status as a single mother of a disabled child rendered her case “exceptional.” In most E.U. countries, drugs are made available through public health systems as soon as they get an E.U. license. But in Britain, drugs must also undergo a cost-benefit analysis.

The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up